Figure 4

CD62L phenotype (after B/I activation and expansion) of T cells mediating tumor regression. Mice with established 4T1 flank tumors were either untreated, treated with CYP alone (100 mg/kg i.p. on day 3) or CYP + AIT (on day 4) with 10 × 10⁶ unsorted, CD62L⁺ or CD62^- B/I activated tumor-sensitized lymphocytes. CD62L separation was performed after B/I activation and expansion for 7 days in culture, just prior to adoptive transfer. Mean tumor sizes ± SE are charted over time. Numbers to the right indicate the number of mice with complete tumor regression per total number of mice in each group. The AIT and CD62L^- AIT groups were significantly different from the untreated group and the CD62L⁺ AIT groups [F(4,29) = 15.3889, P < 0.0001].